Hair loss in the era of CGRP inhibition: emerging evidence, mechanisms, and clinical implications. [PDF]
Antanaitytė A +3 more
europepmc +1 more source
Emerging pharmacological targets in migraine therapy: CGRP and beyond. [PDF]
Atraszkiewicz D, Dahiya D.
europepmc +1 more source
Acute migraine treatments in patients above age 65. [PDF]
Shah T +3 more
europepmc +1 more source
Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data. [PDF]
Giacon M, Terrazzino S.
europepmc +1 more source
Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis. [PDF]
Nociti V +27 more
europepmc +1 more source
Atogepant modulates brain connectivity in episodic migraine: a longitudinal exploratory fMRI study. [PDF]
Montisano DA +13 more
europepmc +1 more source
Neurologic Symptoms and Cerebrovascular Events During Atogepant Therapy: A Case Series with Contextual Comparison with a Non-Gepant-Treated Migraine Cohort. [PDF]
Göbel CH +4 more
europepmc +1 more source
Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans. [PDF]
Boinpally RR, Trugman JM.
europepmc +1 more source
Chronic Migraine Resistance: A Case Report Highlights an Overlooked Factors in Family Medicine Clinics. [PDF]
Alshareef MH.
europepmc +1 more source
Calcitonin Gene-Related Peptide (CGRP): Biology, Signaling, Pathophysiological Roles, and Therapeutic Applications. [PDF]
Ramírez-Expósito MJ +2 more
europepmc +1 more source

